Stock Quote | Zynerba Pharmaceuticals Inc The Investor Relations website contains information about Zynerba Pharmaceuticals Inc's business for stockholders, potential investors, and financial analysts. Investor Relations | Zynerba Pharmaceuticals Inc Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery.
Zynerba Reports Positive Results for ZYN002 CBD Gel in Phase 1
ZYN002 CBD gel was shown to be safe and well-tolerated across range of doses tested in healthy subjects and adult epilepsy patients with focal seizuresNo impairment in cognitive performance or | December 5, 2016 Zynerba Pharmaceuticals Announces Positive Top Line Results from
Zynerba shares plunge as cannabis-based epilepsy gel fails study
Zynerba Reports Positive Results for ZYN002 Cannabidiol Gel in Zynerba Pharmaceutical today announced additional results from Phase 1 randomized, double-blind, placebo-controlled single and multiple ascending dose studies of ZYN002 cannabidiol (CBD) gel. Zynerba’s Cannabidiol Gel Eases Anxiety and - Fragile X News Zynerba's Zygel (ZYN002), a cannabidiol gel placed on the skin, was well-tolerated and led to a "clinically meaningful" easing of anxiety and other behavioral symptoms in children and teenagers with fragile X syndrome, according to results of a clinical trial in Australia. The findings, "A phase
Zynerba Pharmaceutical's CBD gel to treat Fragile X syndrome
News zur ZYNERBA PHARMACEUTICALS AKTIE und aktueller Realtime-Aktienkurs NA Proactive news snapshot: Capstone Turbine, Zynerba Pharmaceuticals, Heritage Cannabis, Xphyto Therapeutics … Fragile X Children See Benefits of Cannabidiol Gel ZYN002 in Zynerba Pharmaceuticals’ investigative therapy ZYN002 — a pharmaceutically produced cannabidiol (CBD) gel — was seen to significantly improve behavioral symptoms in children and adolescents with fragile X syndrome (FXS), according to new Phase 2 clinical data. Zynerba Pharmaceuticals Inc: CBD Biotech Stock Up 355% In 2019